Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Robier, C; Amouzadeh-Ghadikolai, O; Bregant, C; Diez, J; Melinz, K; Neubauer, M; Quasthoff, S.
The anti-VLA-4 antibody natalizumab induces erythroblastaemia in the majority of the treated patients with multiple sclerosis.
Mult Scler. 2014; 20(9):1269-1272
Doi: 10.1177/1352458514521307
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Robier Christoph
- Co-Autor*innen der Med Uni Graz
- Quasthoff Stefan
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The presence of erythroblasts in the peripheral blood is generally associated with severe underlying disorders. The anti-very late antigen-4 (anti-VLA-4) antibody natalizumab, which is approved for treatment of multiple sclerosis, mediates an increase in circulating haematopoietic stem cells and may also trigger erythroblastaemia. We investigated the prevalence of erythroblastaemia in sequential blood smears of 14 natalizumab-treated and 14 interferon-treated patients with multiple sclerosis. Erythroblastaemia was found in 13 natalizumab-treated subjects (93%), whereas all controls were negative (p<0.0001). Knowledge of this frequent side effect is crucial for the correct interpretation of blood smears in natalizumab-treated patients and to avoid unnecessary diagnostic procedures. © The Author(s) 2014.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Austria - epidemiology
- Case-Control Studies -
- Erythroblasts - drug effects
- Female -
- Hematologic Diseases - blood
- Hematologic Diseases - chemically induced
- Hematologic Diseases - diagnosis
- Hematologic Diseases - epidemiology
- Humans -
- Immunologic Factors - adverse effects
- Integrin alpha4beta1 - antagonists & inhibitors
- Integrin alpha4beta1 - immunology
- Male -
- Middle Aged -
- Multiple Sclerosis - diagnosis
- Multiple Sclerosis - drug therapy
- Multiple Sclerosis - epidemiology
- Multiple Sclerosis - immunology
- Natalizumab - adverse effects
- Prevalence -
- Risk Factors -
- Treatment Outcome -
- Young Adult -
- Find related publications in this database (Keywords)
- Erythroblastaemia
- erythroblasts
- natalizumab
- multiple sclerosis